Business Description
Novonesis (Novozymes) B
ISIN : US6701081092
Share Class Description:
NVZMY: ADRTotal Employee Number:
11,641Compare
Compare
Traded in other countries / regions
NSIS B.Denmark0Q4U.UKNVZMY.USANZM2.GermanyNZYM.AustriaNSISN.Mexico IPO Date
2009-09-09Description
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | 3.61 | |||||
Interest Coverage | 14.61 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.51 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.8 | |||||
3-Year EBITDA Growth Rate | 0.4 | |||||
3-Year EPS without NRI Growth Rate | 7.4 | |||||
3-Year FCF Growth Rate | 44.2 | |||||
3-Year Book Growth Rate | 51.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 17.01 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.43 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.17 | |||||
9-Day RSI | 73.82 | |||||
14-Day RSI | 68.71 | |||||
3-1 Month Momentum % | 10.87 | |||||
6-1 Month Momentum % | 5.08 | |||||
12-1 Month Momentum % | -0.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.74 | |||||
Quick Ratio | 1.04 | |||||
Cash Ratio | 0.26 | |||||
Days Inventory | 148.48 | |||||
Days Sales Outstanding | 62.55 | |||||
Days Payable | 65.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.45 | |||||
Dividend Payout Ratio | 0.4 | |||||
3-Year Dividend Growth Rate | 5.5 | |||||
Forward Dividend Yield % | 1.45 | |||||
5-Year Yield-on-Cost % | 1.64 | |||||
3-Year Average Share Buyback Ratio | -19 | |||||
Shareholder Yield % | -0.67 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.9 | |||||
Operating Margin % | 21.46 | |||||
Net Margin % | 14.7 | |||||
EBITDA Margin % | 19.81 | |||||
FCF Margin % | 17.92 | |||||
OCF Margin % | 30.73 | |||||
ROE % | 5.81 | |||||
ROA % | 3.84 | |||||
ROIC % | 4.58 | |||||
3-Year ROIIC % | 1.59 | |||||
ROC (Joel Greenblatt) % | 24.34 | |||||
ROCE % | 5.7 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 43.77 | |||||
Forward PE Ratio | 29.87 | |||||
PE Ratio without NRI | 27.48 | |||||
Shiller PE Ratio | 37.97 | |||||
Price-to-Owner-Earnings | 73.85 | |||||
PEG Ratio | 12.49 | |||||
PS Ratio | 6.44 | |||||
PB Ratio | 2.48 | |||||
Price-to-Tangible-Book | 767.83 | |||||
Price-to-Free-Cash-Flow | 36.08 | |||||
Price-to-Operating-Cash-Flow | 21.04 | |||||
EV-to-EBIT | 35.87 | |||||
EV-to-Forward-EBIT | 29.86 | |||||
EV-to-EBITDA | 35.87 | |||||
EV-to-Forward-EBITDA | 18.68 | |||||
EV-to-Revenue | 7.09 | |||||
EV-to-Forward-Revenue | 7.02 | |||||
EV-to-FCF | 39.57 | |||||
Price-to-GF-Value | 1.02 | |||||
Price-to-Projected-FCF | 2.07 | |||||
Price-to-DCF (Earnings Based) | 2.03 | |||||
Price-to-DCF (FCF Based) | 2.66 | |||||
Price-to-Median-PS-Value | 0.99 | |||||
Price-to-Graham-Number | 30.85 | |||||
Earnings Yield (Greenblatt) % | 2.79 | |||||
FCF Yield % | 2.78 | |||||
Forward Rate of Return (Yacktman) % | -1.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NVZMY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novonesis (Novozymes) B Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4,996.795 | ||
| EPS (TTM) ($) | 1.579 | ||
| Beta | 0.541 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.45 | ||
| Volatility % | 15.29 | ||
| 14-Day RSI | 68.71 | ||
| 14-Day ATR ($) | 2.036296 | ||
| 20-Day SMA ($) | 64.98575 | ||
| 12-1 Month Momentum % | -0.98 | ||
| 52-Week Range ($) | 49.9 - 75.265 | ||
| Shares Outstanding (Mil) | 466.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novonesis (Novozymes) B Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novonesis (Novozymes) B Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 09:00 | In 78 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 77 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 09:00 | 69.51 (+8.12%) | ||
| Second quarter earnings results for 2026 | 2026-08-19 | 64.19 (+0.64%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 09:00 | 62.33 (+0.16%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 62.33 (+0.16%) | ||
| USD 0.653343 Cash Dividend | 2026-03-25 | 56.25 (+2.91%) | ||
| General meeting for 2026 | 2026-03-23 16:00 | 54.11 (-0.77%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 09:00 | 60.74 (-0.75%) | ||
| Annual report for 2025 | 2026-02-25 | 60.74 (-0.75%) |
Show
Entries
Novonesis (Novozymes) B Frequently Asked Questions
What is Novonesis (Novozymes) B(NVZMY)'s stock price today?
The current price of NVZMY is $69.11. The 52 week high of NVZMY is $75.27 and 52 week low is $49.90.
When is next earnings date of Novonesis (Novozymes) B(NVZMY)?
The next earnings date of Novonesis (Novozymes) B(NVZMY) is 2026-11-06 Est..
Does Novonesis (Novozymes) B(NVZMY) pay dividends? If so, how much?
The Dividend Yield %  of Novonesis (Novozymes) B(NVZMY) is 1.45% (As of Today), Highest Dividend Payout Ratio of Novonesis (Novozymes) B(NVZMY) was 0.84. The lowest was 0.35. And the median was 0.48. The  Forward Dividend Yield % of Novonesis (Novozymes) B(NVZMY) is 1.45%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Not Just Yogurt Anymore | 2023-10-26 | ||
| Novozymes Named EPA Safer Choice Partner of the Year for Third Year in a Row | 2023-10-03 |
Articles on Novonesis (Novozymes) B
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers